molecules-logo

Journal Browser

Journal Browser

Asymmetric Synthesis, Chiral Amplification/Enrichment, and Bioactive Chiral Compound Investigation

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Organic Chemistry".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 1364

Special Issue Editor


E-Mail Website
Guest Editor
School of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, China
Interests: absolute configuration determination of chiral (natural) products; asymmetric synthesis; chiral enrichment and amplification; chiral bioactive alkaloids; chiral catalysts

Special Issue Information

Dear Colleagues,

Chiral compounds are important elements in pharmaceuticals, materials, as well as being involved in the origins of life. This Special Issue focuses on the organic stereochemistry study. It contains the chiral catalysts used in asymmetric synthesis of bioactive compounds, chiral enrichment or amplification, the isolation of bioactive chiral compounds and their absolute configuration assignments. Some chiral material characteristics may be included since many chiral materials may be applied for pharmaceutical use. Theoretical study combined with the experimental study are encouraged in the Special Issue. Reviews related in the organic stereochemistry are also welcome.

Dr. Huajie Zhu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chiral bioactive compounds
  • absolute configuration
  • chiral amplification or/and enrichment
  • asymmetric synthesis
  • chiral drug

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 4527 KiB  
Article
Effusanin B Inhibits Lung Cancer by Prompting Apoptosis and Inhibiting Angiogenesis
by Jiantong Hou, Ying Li, Honghong Xing, Ruyu Cao, Xiaomeng Jin, Jing Xu and Yuanqiang Guo
Molecules 2023, 28(23), 7682; https://doi.org/10.3390/molecules28237682 - 21 Nov 2023
Cited by 1 | Viewed by 1089
Abstract
Cancer is one of the deadliest human diseases, causing high rates of illness and death. Lung cancer has the highest mortality rate among all malignancies worldwide. Effusanin B, a diterpenoid derived from Isodon serra, showed therapeutic potential in treating non-small-cell lung cancer [...] Read more.
Cancer is one of the deadliest human diseases, causing high rates of illness and death. Lung cancer has the highest mortality rate among all malignancies worldwide. Effusanin B, a diterpenoid derived from Isodon serra, showed therapeutic potential in treating non-small-cell lung cancer (NSCLC). Further research on the mechanism indicated that effusanin B inhibited the proliferation and migration of A549 cells both in vivo and in vitro. The in vitro activity assay demonstrated that effusanin B exhibited significant anticancer activity. Effusanin B induced apoptosis, promoted cell cycle arrest, increased the production of reactive oxygen species (ROS), and altered the mitochondrial membrane potential (MMP). Based on mechanistic studies, effusanin B was found to inhibit the proliferation and migration of A549 cells by affecting the signal transducer and activator of transcription 3 (STAT3) and focal adhesion kinase (FAK) pathways. Moreover, effusanin B inhibited tumor growth and spread in a zebrafish xenograft model and demonstrated anti-angiogenic effects in a transgenic zebrafish model. Full article
Show Figures

Graphical abstract

Back to TopTop